Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | HPGD | P15428 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7526433 | 0.92 | F10 (0.39) | BRD4ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL7530460 | 0.88 | ALDH1A1 (0.41) | BRD4ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL7526360 | 0.87 | HTR2A (0.44) | BRD4ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL7530659 | 0.87 | KMT2A (0.42) | BRD4ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL13407117 | 0.87 | ALDH1A1 (0.37) | BRD4ALDH1A1HPGDGAAKDM4E | |
| SCHEMBL7526284 | 0.86 | CYP2D6 (0.41) | ALDH1A1HPGDGAAKDM4ECYP3A4 | |
| SCHEMBL7524523 | 0.85 | LMNA (0.45) | ALDH1A1HPGDGAAKMT2ALMNA | |
| SCHEMBL7530815 | 0.85 | GAA (0.51) | ALDH1A1HPGDGAAKDM4EKMT2A | |
| SCHEMBL13407118 | 0.85 | ALDH1A1 (0.49) | BRD4ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL13407130 | 0.84 | ALDH1A1 (0.37) | BRD4ALDH1A1HPGDGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-7973067-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BRD4 2961/4885ALDH1A1 4505/4885HPGD 2404/4885 |
| US-20090258868-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | BRD4 2961/4885ALDH1A1 4505/4885HPGD 2404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.